What Avenzo Therapeutics’ ORION-1 expansion reveals about the next phase of CDK drug development
Find out how Avenzo Therapeutics’ AVZO-023 and AVZO-021 combination study could influence HR+/HER2- breast cancer treatment.
Delphi Diagnostics data challenges one-size-fits-all use of extended endocrine therapy in breast cancer
SABCS data suggests endocrine activity may predict who truly benefits from extended endocrine therapy. Here is what Delphi Diagnostics’ findings mean.